Assessment of Neoadjuvant Chemotherapy (CDDP plus UFT concomitant therapy) in Stage IVb Gastric Cancer Patients

Masamichi Ohtani, Sumio Takayama

Department of Surgery II, Jikei University School of Medicine

We performed cisplatin plus tegafur and uracil therapy as pre-operative chemotherapy in 24 among 90 patients with stage IVb advanced gastric cancer in our department from 1991 to 1996 and report our results in this paper. We obtained an efficacy rate of 46% (CR, 0; PR, 11; NC, 11; PD, 2). In the neoadjuvant chemotherapy (NAC) group, a significant difference in survival time was found between the PR group and the NC/PD group. However the difference in survival time between the group first treated by surgery (66 patients) and the whole NAC group was not significant. Nor was the difference in survival time significant when the PR group in the NAC group was compared with the preceding surgery group. NAC might be effective and enable the lesion to be resected for patients in whom the primary lesion was considered to be unresectable at the pre-operative diagnosis.

Key words
neoadjuvant chemotherapy for gastric cancer, gastric cancer, UFT, CDDP, survival time

Reprint requests
Masamichi Ohtani Department of Surgery II, Jikei University School of Medicine
3-25-8 Nishishinbashi, Minato-ku, Tokvo, 105-8461 JAPAN

Accepted
April 22, 1998

To read the PDF file you will need Abobe Reader installed on your computer.